Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD
Capricorn Fund Managers Ltd has acquired a new stake of 210,674 shares in Amicus Therapeutics (NASDAQ: FOLD), valued at approximately $3.0 million, representing 0.07% of the biopharmaceutical company. This investment comes as Amicus Therapeutics reported a slight EPS miss but a 23.7% year-over-year revenue increase in its Q4 earnings. Despite some insider selling by the CEO, other institutions have increased their positions, and analysts generally rate the stock as a "Hold" with a consensus target price of $15.39.
FOLD Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Amicus Therapeutics Inc (FOLD) as of April 2, 2026. It indicates a "Strong Buy" overall technical sentiment based on a proprietary analysis of 11 technical signals, with 9 buy and 2 sell indicators. The analysis details various technical indicators, moving averages, and support/resistance levels to support its forecast.
FOLD: Acquisition Vote And Rare Disease Franchise Outlook Will Guide Risk Balance
Amicus Therapeutics (FOLD) is facing a pivotal shareholder vote on its acquisition by BioMarin Pharmaceutical, which will significantly influence its future in the rare disease franchise. Analysts maintain a fair value of $14.50 for FOLD, with some bullish views on the combined entity's potential and others expressing caution due to execution risks and concerns about BioMarin's existing assets. The upcoming vote and integration process will be key factors for the stock's performance, outweighing minor adjustments to revenue growth and profit margin expectations.
Amicus Therapeutics stock hits 52-week high at $14.44 By Investing.com
Amicus Therapeutics (FOLD) stock reached a new 52-week high of $14.44, representing an 81.51% increase over the past year. This achievement is backed by a market capitalization of $4.53 billion, an 88.5% gross profit margin, and 20% revenue growth, with analysts predicting profitability this year. Recent developments include shareholder approval for BioMarin Pharmaceutical's acquisition of Amicus Therapeutics and upcoming presentations on Fabry and Pompe disease treatments.
Assessing Amicus Therapeutics (FOLD) Valuation After Strong Long Term Shareholder Returns
This article analyzes the valuation of Amicus Therapeutics (FOLD) following strong long-term shareholder returns, noting a one-year return of 70.94% and a five-year return of 43.24%. While the share price is near its intrinsic value of US$14.50, a narrative suggests it is 60% undervalued due to expanding patient identification for Fabry and Pompe diseases. The potential for sustained long-term revenue growth and margin expansion supports this optimistic outlook, though risks related to concentrated revenue and potential setbacks exist.
Assessing Amicus Therapeutics (FOLD) Valuation After Strong Long Term Shareholder Returns
This article analyzes Amicus Therapeutics (FOLD) valuation, noting recent strong long-term shareholder returns despite muted short-term trading. It highlights a common narrative suggesting the stock is 60% undervalued, with a fair value target of $14.50, driven by expanded patient identification for rare diseases. The article also cautions that this valuation depends on continued revenue from its key products and could be challenged by clinical, regulatory, or pricing setbacks.
210,800 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by CIBRA Capital Ltd
CIBRA Capital Ltd has acquired a new stake of 210,800 shares in Amicus Therapeutics, Inc. (NASDAQ: FOLD) during the fourth quarter, valued at approximately $3.00 million, making it their 11th largest holding. Amicus Therapeutics, a biopharmaceutical company, reported Q4 revenue of $185.21 million, up 23.7% year-over-year, but missed EPS estimates. The article also notes recent insider selling by CEO Bradley Campbell and a mixed "Hold" consensus rating from analysts with an average price target of $15.39.
FOLD PE Ratio & Valuation, Is FOLD Overvalued
Amicus Therapeutics Inc (FOLD) is currently considered "Fairly" valued, with its forward PS ratio of 6.13 being comparable to its five-year average of 5.97. The fair price for FOLD is estimated to be between $11.44 and $18.57 based on relative valuation methods. While FOLD's P/S ratio of 6.13 is above the industry average of 4.83, its strong revenue growth of 23.72% suggests this premium might be sustainable.
JPMorgan Chase & Co. Sells 94,105 Shares of Amicus Therapeutics, Inc. $FOLD
JPMorgan Chase & Co. reduced its stake in Amicus Therapeutics by 4.3% in the third quarter, selling 94,105 shares and retaining ownership of 2,116,166 shares valued at approximately $16.68 million. CEO Bradley L. Campbell also sold 22,500 shares for $322,875, bringing his direct ownership to 998,680 shares. Analyst consensus remains a "Hold" with an average price target of $15.39.
Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week High - What's Next?
Amicus Therapeutics (NASDAQ:FOLD) reached a new 52-week high of $14.43 in mid-day trading but has since seen multiple analyst downgrades, resulting in a consensus "Hold" rating and an average price target of $15.39. The company reported quarterly EPS of $0.10, missing estimates, though revenue of $185.21 million largely met expectations and increased 23.7% year-over-year. Insider selling by the CEO and varied institutional trading activity have also been noted.
FOLD: Acquisition Vote And Mixed BioMarin Outlook Will Shape Future Risk Balance
Amicus Therapeutics (FOLD) fair value remains steady at $14.50 despite mixed analyst outlooks on its merger with BioMarin Pharmaceutical, with the acquisition vote scheduled for March 3, 2026. Bullish analysts focus on potential growth and financial flexibility from the combined entity, while bearish views highlight risks like product specific headwinds and integration challenges. The valuation adjustments include a slight decrease in discount rate and revenue growth, an increase in net profit margin, and a reduction in future P/E.
FOLD Should I Buy
Amicus Therapeutics Inc (FOLD) is not recommended as a strong buy for beginner long-term investors due to weak financial performance, cautious analyst sentiment, and a lack of significant bullish momentum. Despite its growth potential in rare disease therapies, recent downgrades and mixed technical indicators suggest holding off on investment. The stock's latest price is $14.380, with analysts forecasting an average price target of $14.79.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Hold" from Analysts
Amicus Therapeutics (NASDAQ:FOLD) has received a consensus "Hold" rating from thirteen analysts, with an average 12-month price target of $15.39. This comes after mixed quarterly results, where the company missed EPS expectations but reported a 23.7% increase in revenue year-over-year. Despite recent insider selling, major institutional investors have established or increased their positions in the biopharmaceutical company.
872,411 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by Ion Asset Management Ltd.
Ion Asset Management Ltd. recently acquired 872,411 shares of Amicus Therapeutics (FOLD) for approximately $6.88 million, making it their 24th largest holding. Despite this significant investment, analyst sentiment for Amicus Therapeutics has shifted to a "Hold" rating with an average target price of $15.39, following several downgrades. The company reported Q4 results with a slight miss on EPS ($0.10 vs. $0.13 expected) but showed a 23.7% year-over-year revenue increase to $185.21 million.
Elevation Point Wealth Partners LLC Makes New Investment in Amicus Therapeutics, Inc. $FOLD
Elevation Point Wealth Partners LLC has made a new investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD), acquiring 375,720 shares valued at approximately $2.96 million. This move comes as other institutional investors have also adjusted their positions in the biopharmaceutical company, despite analysts generally having a "Hold" rating on the stock with a consensus target price of $15.39. Amicus Therapeutics recently missed its EPS estimates for the last quarter, though revenue was in line with expectations and showed significant year-over-year growth, while insiders have been net sellers of the stock.
Assessing Amicus Therapeutics (FOLD) Valuation After Strong Recent Share Price Momentum
Amicus Therapeutics (FOLD) has seen significant share price momentum, with a 32.1% return in the last three months and 61.5% over the past year. Despite its current price of $14.37 being close to the analyst target of $14.50, the company is considered undervalued based on long-term cash flow models, driven by anticipated revenue growth, improved profitability, and a higher future earnings multiple. Investors are advised to consider execution risks related to concentrated revenues and potential capital raises, alongside the positive outlook.
Amicus Therapeutics, Inc. $FOLD Shares Sold by Prosight Management LP
Prosight Management LP significantly reduced its stake in Amicus Therapeutics (FOLD) by over 50%, selling 1.77 million shares. This move aligns with recent insider selling activities and a general cooling of analyst sentiment, leading to multiple downgrades to "Hold" or "Market Perform." Despite mixed institutional investor activity and revenue meeting expectations, the company missed EPS estimates, contributing to the cautious outlook.
Assessing Amicus Therapeutics (FOLD) After Strong One Year Share Price Performance
Amicus Therapeutics (FOLD) has seen a 61.6% return over the last year, with its stock currently trading around US$14.37. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 76.6%, with an estimated intrinsic value of US$61.35 per share. The company's Price-to-Sales (P/S) ratio of 7.11x is below its Fair Ratio of 8.36x, further indicating potential undervaluation, while narratives from analysts offer both bullish (US$14.50) and bearish (US$9.00) fair value perspectives based on different assumptions.
Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis
Genomenon and Amicus Therapeutics have announced a strategic partnership to enhance awareness, diagnosis, and research for Fabry disease. Through this collaboration, Genomenon has curated over 1,300 variants in the GLA gene, including more than 1,000 pathogenic or likely pathogenic variants, and made this data publicly accessible via the Mastermind Genomic Intelligence Platform and ClinVar. This initiative aims to accelerate the genetic diagnosis of Fabry disease by providing clinicians with comprehensive and high-quality genetic insights.
Amicus Therapeutics (FOLD) CEO Bradley Campbell sells 22,500 shares in open market
Amicus Therapeutics President and CEO Bradley L. Campbell sold 22,500 shares of common stock at a weighted average price of $14.3484 per share on March 2, 2026. After this transaction, he still holds 998,680 shares of the company's common stock directly. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025.
FOLD: Acquisition Progress And Mixed BioMarin Outlook Will Shape Measured Risk Profile
Amicus Therapeutics' fair value remains at $14.50, influenced by its impending acquisition by BioMarin and recent analyst commentary. Bullish analysts view the acquisition as a positive for BioMarin's rare disease portfolio and diversification, while bearish analysts express concerns over execution risk, integration challenges, and the price paid for Amicus. The deal, valued at $4.7 billion, is expected to close in Q2 2026, with a special shareholder meeting scheduled for March 3, 2026.
FOLD SEC Filings - Amicus Therapeut 10-K, 10-Q, 8-K Forms
This article provides details on Amicus Therapeutics (FOLD) SEC filings, including 10-K, 10-Q, and 8-K forms, accessible through Stock Titan. It highlights key events such as the proposed acquisition by BioMarin Pharmaceutical Inc., insider stock transactions, and quarterly financial results, detailing product revenues and financial positions. The platform also offers AI-powered tools to help analyze these regulatory documents.
Insider Sell: Bradley Campbell Sells 22,500 Shares of Amicus The
Amicus Therapeutics Inc (FOLD) President and CEO, Bradley Campbell, sold 22,500 shares of the company on March 2, 2026. Following this transaction, Campbell now owns 998,680 shares. The stock is considered fairly valued based on its GuruFocus Value, which is calculated using historical multiples, a GuruFocus adjustment factor, and future business performance estimates from Morningstar analysts.
JPMorgan Chase & Co. Has $16.68 Million Stock Position in Amicus Therapeutics, Inc. $FOLD
JPMorgan Chase & Co. reduced its stake in Amicus Therapeutics (NASDAQ:FOLD) by 4.3% in the third quarter, holding 2.12 million shares valued at $16.68 million. Several other hedge funds also adjusted their positions in the biopharmaceutical company during the quarter. Amicus Therapeutics stock opened at $14.34, with recent earnings missing analyst estimates, while analysts currently hold a consensus "Hold" rating and a price target of $15.39.
Is It Too Late To Consider Amicus Therapeutics (FOLD) After The Proposed BioMarin Deal Price?
This article analyzes Amicus Therapeutics (FOLD) after its proposed BioMarin deal price of US$14.50. It uses discounted cash flow (DCF) and price-to-sales (P/S) analyses, both suggesting the stock is undervalued, with the DCF model indicating a 76.5% undervaluation compared to its current price of US$14.34. The article also presents "Narratives" for investors to weigh bullish and bearish cases, factoring in the potential acquisition and risks like product concentration.
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical
Amicus Therapeutics shareholders have approved the company's acquisition by BioMarin Pharmaceutical, satisfying a major condition for the merger. The merger proposal passed with overwhelming support, and an advisory vote on executive compensation also received approval. While the U.S. Federal Trade Commission granted early termination of the Hart-Scott-Rodino waiting period, the transaction, expected to close in Q2 2026, still requires regulatory clearances from certain non-U.S. jurisdictions.
Vanguard Group Inc. Buys 126,441 Shares of Amicus Therapeutics, Inc. $FOLD
Vanguard Group Inc. increased its stake in Amicus Therapeutics (NASDAQ:FOLD) by 0.4% in the third quarter, acquiring an additional 126,441 shares, bringing its total holding to over 29.5 million shares valued at approximately $232.7 million. Analyst ratings for Amicus Therapeutics are mixed, with a consensus "Hold" rating and a $15.39 target price, while insiders have been net sellers, including CEO Bradley L. Campbell. The company reported $185.21 million in revenue and $0.10 EPS for its latest quarter, missing consensus EPS estimates.
William Blair Investment Management LLC Buys 1,107,083 Shares of Amicus Therapeutics, Inc. $FOLD
William Blair Investment Management LLC significantly increased its stake in Amicus Therapeutics, purchasing over 1.1 million shares to own 5.10% of the company. Despite mixed analyst sentiment with an average "Hold" rating, several other institutional investors also adjusted their positions in FOLD. The company recently reported Q4 earnings, missing EPS estimates but showing a 23.7% year-over-year revenue increase, while insiders sold a notable amount of stock.
Fox Run Management L.L.C. Takes $553,000 Position in Amicus Therapeutics, Inc. $FOLD
Fox Run Management L.L.C. has acquired a new position in Amicus Therapeutics, purchasing 70,115 shares valued at approximately $553,000 in the third quarter. While institutional investors like Vanguard and Vestal Point Capital have increased their stakes, analysts largely maintain a "Hold" rating on the stock with an average price target of $15.39. Amicus Therapeutics recently missed EPS estimates but showed strong revenue growth, though insider selling by the CEO and other executives has also been noted.
BioMarin Deal Reshapes Amicus Therapeutics Outlook For Growth And Portfolio
BioMarin Pharmaceutical's acquisition of Amicus Therapeutics is set to significantly alter Amicus's commercial portfolio and growth trajectory, especially impacting its rare disease treatments like Galafold and Pombiliti + Opfolda. The $4.8 billion deal aims to integrate Amicus's assets and pipeline into BioMarin's global infrastructure, shifting Amicus's focus from a standalone specialist to a part of a larger biopharmaceutical entity. Investors are advised to monitor regulatory and shareholder approvals, the scheduled Q2 2026 closing, and potential shifts in product priorities.
BioMarin Deal Reshapes Amicus Therapeutics Outlook For Growth And Portfolio
BioMarin Pharmaceutical has agreed to acquire Amicus Therapeutics in a deal that significantly alters Amicus's future and commercial portfolio, valued at US$4.8 billion. The acquisition, expected to close in Q2 2026, will integrate Amicus's key therapies like Galafold and Pombiliti + Opfolda into BioMarin's global rare disease portfolio. This move transitions Amicus from a standalone specialist to a part of a larger entity, focusing investor attention on integration, regulatory approvals, and shifts in product priorities.
Precision Trading with Amicus Therapeutics Inc. (FOLD) Risk Zones
Amicus Therapeutics Inc. (FOLD) is exhibiting a neutral near and mid-term outlook, with a mid-channel oscillation pattern observed. Despite this, a strong long-term positive bias remains, and aggressive short-term trading signals are present. The article details multi-timeframe signal analysis and institutional trading strategies, including specific entry, target, and stop-loss zones for position trading, momentum breakout, and risk hedging.
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 3 Month Share Price Rally
Amicus Therapeutics (FOLD) has seen a significant share price rally, with a 45% return over the last three months and over 50% in the last year. Despite a net loss of US$27.11 million on revenues of US$634.21 million, the stock is currently trading close to its fair value of $14.50, suggesting it is about right priced. The company's valuation hinges on expanding patient identification for Fabry and Pompe diseases and continued execution of its key products.
Amicus Therapeutics: Fourth Quarter Financial Results Overview
Amicus Therapeutics reported a net profit of $1.7 million, or $0.01 per share, for the fourth quarter, with adjusted earnings of $0.10 per share falling below analyst expectations of $0.13. However, the company's revenue of $185.2 million surpassed the Zacks consensus estimate of $179.9 million. For the full year, Amicus Therapeutics posted a net loss of $27.1 million on total revenue of $634.2 million.
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues
Amicus Therapeutics (FOLD) reported Q4 2025 adjusted earnings of 10 cents per share, missing the Zacks Consensus Estimate, despite revenues growing 24% year-over-year to $185.2 million, surpassing estimates. The revenue growth was driven by sales of Galafold and the new combo drug Pombiliti + Opfolda. BioMarin Pharmaceutical (BMRN) is set to acquire Amicus for $4.8 billion, a deal expected to close in Q2 2026.
Amicus Therapeutics: Q4 Earnings Snapshot
Amicus Therapeutics Inc. reported a fourth-quarter net income of $1.7 million, or 1 cent per share, with adjusted earnings of 10 cents per share falling short of Wall Street's expectation of 13 cents. The pharmaceutical company's revenue of $185.2 million, however, exceeded analysts' forecasts. For the full year, Amicus Therapeutics reported a loss of $27.1 million on revenues of $634.2 million.
Amicus Therapeutics: Q4 Earnings Snapshot
Amicus Therapeutics Inc. (FOLD) reported a fourth-quarter net income of $1.7 million, or 1 cent per share, adjusted to 10 cents per share. This fell short of analyst expectations of 13 cents per share. However, the company's revenue of $185.2 million for the quarter exceeded Street forecasts.
Amicus Therapeutics Q4 Highlights: Revenue Growth Amid Losses
Amicus Therapeutics reported a 24% year-over-year increase in Q4 net product revenue, driven by strong sales of Galafold and Pombiliti + Opfolda. Despite this growth, net income plummeted due to increased share-based compensation expenses, though the full year 2025 saw an improvement in adjusted net income and a narrowed net loss. The company is set to be acquired by BioMarin Therapeutics for approximately $4.8 billion in Q2 2026.
Amicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives
Amicus Therapeutics (FOLD) reported mixed Q4 2025 results, with revenue of US$185.2 million and positive basic EPS of US$0.01, but a trailing 12-month net loss of US$27.1 million. While quarterly net income turned positive, the full year still indicates a loss, challenging bullish narratives about profitability and growth. Investors are looking for sustained improvements in net income to solidify the company's financial standing and justify long-term growth forecasts.
Amicus Therapeutics (NASDAQ:FOLD) Announces Quarterly Earnings Results
Amicus Therapeutics (NASDAQ:FOLD) reported its quarterly earnings, with an EPS of $0.10, missing the consensus estimate of $0.13. The company's revenue of $185.21 million was largely in line with expectations. Despite a negative net margin of 2.35%, Amicus Therapeutics showed a positive return on equity of 6.95%, and its stock traded near its 12-month high.
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Amicus Therapeutics reported strong full-year 2025 financial results, with total revenue reaching $634.2 million, an increase of 17% year-over-year at constant exchange rates. The company also announced a cash position of $293.5 million, a $44 million increase from the previous year. Amicus's proposed acquisition by BioMarin for $4.8 billion is expected to close in Q2 2026, with regulatory clearances already underway.
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Amicus Therapeutics has announced its full-year 2025 financial results, reporting significant revenue growth and improved financial performance. The company's total revenues reached $634.2 million, a 17% increase year-over-year, driven by strong sales of Galafold and Pombiliti + Opfolda. Amicus also revealed its definitive agreement to be acquired by BioMarin Therapeutics for approximately $4.8 billion, a transaction expected to close in Q2 2026.
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Amicus Therapeutics reported strong full-year 2025 financial results, with total revenues reaching $634.2 million, a 17% increase year-over-year at constant exchange rates. The company also announced a cash position of $293.5 million, up $44 million from 2024. These results come as Amicus anticipates its acquisition by BioMarin Therapeutics, expected to close in Q2 2026.
AMICUS THERAPEUTICS, INC. SEC 10-K Report
Amicus Therapeutics, Inc. has released its annual Form 10-K report, detailing significant financial growth with net product sales of $634.2 million and a reduced net loss, driven by the strong performance of Galafold® and Pombiliti® + Opfolda®. The report highlights strategic initiatives including new product launches, pipeline expansion through licensing DMX-200, and a pending merger with BioMarin Pharmaceutical Inc. The company also addresses key challenges and risks, such as the BioMarin transaction, reliance on key products, and regulatory and market risks.
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Amicus Therapeutics announced strong financial results for full-year 2025, with total revenue reaching $634.2 million, an increase of 17% year-over-year at constant exchange rates. The company also reported a significant increase in its cash position to $293.5 million. Furthermore, Amicus provided updates on its proposed acquisition by BioMarin Therapeutics for approximately $4.8 billion, which is expected to close in Q2 2026, and highlighted new data presented on its Fabry and Pompe disease treatments.
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Amicus Therapeutics reported strong full-year 2025 financial results, with total revenue reaching $634.2 million, marking a 17% increase year-over-year at constant exchange rates. The company also announced a proposed acquisition by BioMarin for $4.8 billion, expected to close in Q2 2026, and highlighted positive clinical data for its key products, Galafold and Pombiliti + Opfolda.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Hold" by Brokerages
Amicus Therapeutics (NASDAQ:FOLD) has received a consensus "Hold" recommendation from fourteen brokerages, with an average one-year target price of $15.55. Recent insider transactions show significant selling, with insiders offloading 394,807 shares in the last 90 days, reducing their ownership to 2.20%. Despite insider selling, the fourth quarter saw substantial institutional buying from firms like HBK Investments, Pentwater Capital Management, Soros Fund Management, and UBS Group AG.
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections
TD Cowen has maintained a Hold rating on Amicus Therapeutics (FOLD) with a $14.50 price target, despite the company's strong fourth-quarter and full-year 2025 revenue performance, particularly from its Fabry disease medication, Galafold. The cautious stance is primarily due to BioMarin's agreement to acquire Amicus for $14.50 per share, which limits the potential for significant share price appreciation beyond deal-spread dynamics as the acquisition is expected to close by Q2 2026. Amicus Therapeutics specializes in developing medicines for metabolic diseases.
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections
TD Cowen has maintained a Hold rating and a $14.50 price target on Amicus Therapeutics (FOLD), despite the company's Q4 and full-year 2025 revenue exceeding expectations, primarily due to strong performance from its Fabry disease medication, Galafold. The caution stems from BioMarin's agreement to acquire Amicus for $14.50 per share, which limits the potential for further stock appreciation beyond deal-spread dynamics and low-probability transaction risks. The acquisition is expected to close by Q2 2026, subject to regulatory and shareholder approvals.
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC
MLex reported that BioMarin Pharmaceutical Inc.'s $4.8 billion acquisition of Amicus Therapeutics received early termination approval from the US Federal Trade Commission. This decision came on February 11, ahead of the Hart-Scott-Rodino Act waiting period's original expiration date of February 20. The transaction is anticipated to conclude in the second quarter of 2026.
